Compare SWRD & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWRD | PHAT |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 593.4M | 590.6M |
| IPO Year | 2025 | 2019 |
| Metric | SWRD | PHAT |
|---|---|---|
| Price | $3.14 | $5.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $20.05 |
| AVG Volume (30 Days) | 238.9K | ★ 1.7M |
| Earning Date | 11-17-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $79.63 |
| Revenue Next Year | N/A | $54.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $1.79 | $5.02 |
| 52 Week High | $3.57 | $18.31 |
| Indicator | SWRD | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 61.73 | 34.30 |
| Support Level | $2.26 | $5.02 |
| Resistance Level | $3.57 | $7.72 |
| Average True Range (ATR) | 0.35 | 0.62 |
| MACD | 0.05 | -0.06 |
| Stochastic Oscillator | 68.16 | 28.10 |
Stewards Inc is a diversified financial services company with two complementary business platforms: Private Credit and Real Estate. It provides alternative financing solutions to small and medium-sized businesses (SMBs) underserved by traditional lenders, while also building a portfolio of income-producing and value enhancing real estate assets. The Private Credit Division provides revenue-based funding and related financing products to SMBs nationwide. The Real Estate Division targets strategic investments in residential, mixed-use, and commercial properties designed to generate stable rental income and have the potential for long-term value appreciation. It operates in two segments Financing Solutions, and Real Estate Operations.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.